Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 23, 2024, reports on an underwritten follow-on offering closed by Haoxi Health Technology Limited on September 20, 2024. The filing details the terms of the capital raise and the issuance of securities to the public.
Key Financial Metrics
- Gross Proceeds: $12,000,000 generated from the sale of 4,000,000 Units at $3.00 per Unit.
- Offering Price: $3.00 per Unit.
- Net Proceeds: Not specified; filing states gross proceeds are before deducting offering expenses.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The primary material change is the significant increase in capital and potential share count due to the follow-on offering. The Company issued 4,000,000 Units, each consisting of:
- One Class A Ordinary Share (or one Pre-Funded Warrant).
- One Series A Warrant (initially exercisable at $3.00, adjustable to $0.60).
- One Series B Warrant (exercisable at $0.0001).
Specific warrant mechanics include an adjustment on the 16th calendar day post-closing where the Series A Warrant exercise price drops to $0.60, and the maximum shares issuable increase to 20,000,000. The Series B Warrants allow for the issuance of up to 16,000,000 shares at a nominal price.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard warrant terms. Key contingencies include:
- Adjustments: Exercise prices and share counts are subject to adjustment for stock dividends, splits, or reclassifications.
- Fundamental Transactions: In the event of a merger or change of control, warrant holders may receive securities, cash, or a cash payment based on the Black-Scholes value of the warrant.
- Underwriting: The offering was conducted via EF Hutton LLC as the representative underwriter.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting fees and offering expenses.
- Confirm the exact number of Pre-Funded Warrants versus Class A Ordinary Shares issued in the 4,000,000 Units.
- Monitor the Series B Exercise Date (16 days post-closing) for the adjustment of Series A Warrant terms.
- Review the full Underwriting Agreement (Exhibit 99.1) for lock-up periods or additional covenants.
- Assess the dilution impact of the potential 36,000,000+ shares issuable upon full exercise of all warrants.